(Reuters) -Danish drugmaker Novo Nordisk has secured the global rights to develop, manufacture and sell China-based United ...

Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G ...

A recent follow-up assessment at the USTC hospital's multidisciplinary weight management clinic demonstrated the efficacy of ...

Drugmaker Novo Nordisk A/S (NVO) on Monday entered into an exclusive license agreement worth up to $2 billion with ...

Obesity in girls rose to 7.7% in 2022 from 0.6% in 1990. “Obesity has become a major public health issue in China, ranking as the sixth leading risk factor for death and disability in the ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. China’s obesity crisis is a sizeable profit opportunity. More than half of Chinese adults are overweight ...

Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity ...

The three countries expected to have the highest rates of overweight or obesity by 2050 are China (627 million people), India (450 million) and the U.S. (214 million). The study also found that by ...

Novo Nordisk is expanding its pipeline of obesity medicines, announcing Monday it will pay China-based United Laboratories International Holdings $200 million upfront to license an experimental ...

The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.